CV Sciences, Inc. is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company's specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

For the nine months ended September 30, 2018, CVSI reported sales of $34 million, 153% increase as compared to the same period in 2017.

The gross profit increased by 164% to $24.56 million for the nine months ended September 30, 2018.

Both growth investors and value investors should find very appealing that CFO increased by 1,434% for the nine months ended September 30, 2018.

With revenue growth of 153% in the nine months ended September 30, 2018 and large gross profit margin, CV Sciences (OTCQB:CVSI) should trade at about 60x-80x forward sales like other marijuana operators. Assuming these ratios, the stock should trade at $57-$76. As of November 12, 2018, the upside potential is impressive as the share price is below $5. That’s not all. The most recent reports show a drastic decrease in the amount of convertible debt and financial debt.

"With a pipeline of popular products, an entrenched and growing retail footprint, consistently strong operating results, and a history of stock outperformance, CV Sciences is poised for future big gains in 2019. This marijuana company smells like money, not tulips."